

## CURRICULUM VITAE

### Sang Sup Chung, MD, PhD



**Address:** Department of Neurosurgery,  
CHA Bundang Medical Center, CHA University  
59 Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea  
Tel: +82-31-780-5260, Fax: +82-31-780-5269  
E-mail: sschung@cha.co.kr

- |              |  |
|--------------|--|
| 1965         | Graduated from College of Medicine, Yonsei University, Seoul, Korea  |
| 1965-1970    | Neurosurgical Residency, Yonsei University Medical Center, Korea   |
| 1975-1978    | Clinical Assistant and Post-Doctoral Fellow,<br>Department of Surgical Neurology, University of Edinburgh, Edinburgh, United Kingdom                 |
| 1970-1972    | Instructor and Chief, Department of Neurosurgery, Kyungpook National University<br>College of Medicine, Daegu, Korea                                 |
| 1972-2003    | Instructor, Assistant professor, Associate professor & Professor, Department of<br>Neurosurgery, Yonsei University College of Medicine, Seoul, Korea |
| 2003-Present | Professor, Department of Neurosurgery, CHA University College of Medicine,<br>Seongnam, Korea  |

### Medical Societies

- |           |  |
|-----------|--|
| 1990-1992 | President, the Korean Society for Stereotactic & Functional Neurosurgery         |
| 1992-1994 | President, the Korean Neurosurgical Society                                      |
| 1996-2004 | President, Asian-Australian Society for Stereotactic and Functional Neurosurgery |
| 2013      | Spiegel-Wycis Award  |



# Clinical Trial of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients with Parkinson's Disease: Preliminary Report

**Sang Sup Chung, MD**

*Department of Neurosurgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea*

**Objective:** To investigate the safety and efficacy of FMD-NPC (fetal mesencephalic dopamine neuronal precursor cell) after transplantation in patients with idiopathic Parkinson's disease.

**Methods:** Fifteen patients were divided into 3 groups: A (low dosage group), B (medium dosage group), and C (Large dosage group). Each participant had stereotactic transplantation of FMD-NPC at 4 points into the both side of putamen. Participants underwent serial neurological, and radiological evaluation with the United Parkinson Disease Rating Scale (UPDRS) and movement disorder society (MDS)-UPDRS: preoperatively, within 1 week postoperatively, 1 month, 3 month, 6 month, 9 month, and 12 month postoperatively.

**Results:** The mean UPDRS score has minimal change from 35.2 (SD, 6.38) to 33.6 (SD, 10.74) in low dosage group at 12 month postoperatively, while medium dosage group improved from 44.0 (SD, 9.92) to 36.7 (SD, 0) at 9 month postoperatively. MDS-UPDRS score also changed from 29.2 (SD, 8.2) to 25.8 (SD, 6.22) at 12 month in low dosage group, and from 34.4 (SD 7.47) to 29.3 (SD, 0) at 9 month in medium dosage group. No statistical significance is observed at this point. No severe adverse effects were reported during this period. Magnetic resonance image of low dosage group at 12 month after transplantation showed no inflammatory or oncogenic change.

**Conclusion:** We could confirm no adverse effects of FMD-NPC in low dosage group. For medium dosage group, although the follow up period is not enough, we could see some possibility of favorable results.

MEMO

